Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are:Is there an association between iron and alpha-synuclein accumulation in ischemic stroke?Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?

Inclusion Criteria:Patients at the age between 50-70 years.Patients having neurological symptoms of acute ischemic stroke.Exclusion Criteria:Patients with acute hemorrhagic stroke.Patients with Parkinson's disease (PD).Patients with dementia, and Alzheimer's disease.Patients with any type of malignancy.Patients with central nervous system infection.